AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated August 14, 2025, titled "Press Release".
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India reported its Q1 FY25-26 results (April–June 2025), with total revenue rising 36% year-on-year to ₹5,263.1 million from ₹3,875.2 million a year ago. Profit before exceptional items and tax nearly doubled to ₹750.6 million (from ₹424.0 million), and the company swung to a profit after exceptional items and tax of ₹558.3 million versus a loss of ₹117.9 million in the same quarter last year. The Oncology segment led growth with revenue of ₹3,702.7 million (up from ₹2,394.2 million), while Biopharmaceuticals dipped slightly to ₹1,183.2 million. The company also secured four new CDSCO approvals, including expanded indications for Osimertinib in lung cancer, trastuzumab deruxtecan in breast cancer, and Benralizumab, and won the OPPI Medical Excellence Award 2025.
Strong revenue growth, a clean swing back to profit, and a pipeline of new approvals — especially in Oncology — are positive signals for shareholders. The stock may get a short-term lift on the back of the earnings beat and regulatory wins, though Biopharmaceuticals softness is worth watching.